Crossmark

Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation

Crossref DOI link: https://doi.org/10.1186/s12885-024-12797-3

Published Online: 2024-08-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shi, Yuequan

Xu, Yan http://orcid.org/0000-0002-2832-2664
Wang, Mengzhao http://orcid.org/0000-0002-9226-5393
Funding

Funding for this research was provided by:

Capital’s Funds for Health Improvement and Research (2022-2Z-4017)

National High Level Hospital Clinical Research Funding (2022-PUMCH-C-054, 2022-PUMCH-B-106)
License Information

Text and Data Mining valid from 2024-08-23

Version of Record valid from 2024-08-23
More Information

Article History

Received: 11 September 2023

Accepted: 12 August 2024

First Online: 23 August 2024

Declarations

:

: The ethics committee of Peking Union Medical College Hospital approved all experimental protocols. Informed consent was obtained from all of the physicians who participated in this survey.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below